drugset / Trial / NCT07700329

A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants

NCT07700329

Phase 1 Not yet recruiting 16 enrolled Celgene Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the drug levels, safety and tolerability of BMS-986368 in healthy Chinese participants

Timeline

Start
2027-01-05
Primary completion
2027-02-23
Completion
2027-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986368 Unknown

Indications

No indication recorded.